Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.

NCT01419925 is registered in ClinicalTrials.gov with BiondVax Pharmaceuticals ltd. as lead sponsor.

NCT NCT01419925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01419925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.
Lead sponsor
BiondVax Pharmaceuticals ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
January 31, 2012
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, influenza